Literature DB >> 23878165

Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.

M Vivinus-Nébot1, G Frin-Mathy, H Bzioueche, R Dainese, G Bernard, R Anty, J Filippi, M C Saint-Paul, M K Tulic, V Verhasselt, X Hébuterne, T Piche.   

Abstract

OBJECTIVE: To determine the role of colonic barrier defects and low-grade inflammation in irritable bowel syndrome (IBS)-like symptoms in quiescent inflammatory bowel disease (IBD).
DESIGN: Caecal biopsies were collected from 51 IBS, 49 quiescent IBD (31 Crohn's disease (CD) and 18 ulcerative colitis (UC)) patients and 27 controls. IBS was assessed using the Rome III criteria and the IBS severity score. Epithelial barrier integrity was evaluated by determining the paracellular permeability of biopsies mounted in Ussing chambers and the mRNA expression of tight junction proteins (ZO-1, α-catenin and occludin). Low-grade inflammation was evaluated by counting cells, including intraepithelial lymphocytes (IELs), eosinophils and mast cells, and by determining the mRNA and protein expression of tumour necrosis factor (TNF)-α in biopsies and culture supernatants.
RESULTS: IBS-like symptoms were present in 35.4 and 38% of CD and UC patients, respectively. Paracellular permeability was significantly increased in both quiescent IBD with IBS-like symptoms and IBS compared with quiescent IBD without IBS-like symptoms (p<0.01, respectively) or controls (p<0.01, respectively). Significantly lower expression of ZO-1 and α-catenin was detected in IBS and quiescent IBD with IBS-like symptoms. IELs and TNF-α were significantly increased in quiescent IBD with IBS-like symptoms, but not in IBS.
CONCLUSIONS: In quiescent IBD, IBS-like symptoms related to persistent subclinical inflammation associated with increased colonic paracellular permeability. A persistent increase in TNF-α in colonic mucosa may contribute to the epithelial barrier defects associated with abdominal pain in quiescent IBD, but not in IBS. Optimisation of anti-inflammatory therapy may be considered in quiescent IBD with IBS-like symptoms.

Entities:  

Keywords:  ABDOMINAL PAIN; INFLAMMATORY BOWEL DISEASE; IRRITABLE BOWEL SYNDROME; TIGHT JUNCTION; TNF-ALPHA

Mesh:

Substances:

Year:  2013        PMID: 23878165     DOI: 10.1136/gutjnl-2012-304066

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  118 in total

Review 1.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 2.  Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon.

Authors:  Gary M Mawe
Journal:  J Clin Invest       Date:  2015-03-02       Impact factor: 14.808

3.  Bone Marrow-Derived Cells Restore Functional Integrity of the Gut Epithelial and Vascular Barriers in a Model of Diabetes and ACE2 Deficiency.

Authors:  Yaqian Duan; Ram Prasad; Dongni Feng; Eleni Beli; Sergio Li Calzi; Ana Leda F Longhini; Regina Lamendella; Jason L Floyd; Mariana Dupont; Sunil K Noothi; Gopalkrishna Sreejit; Baskaran Athmanathan; Justin Wright; Amanda R Jensen; Gavin Y Oudit; Troy A Markel; Prabhakara R Nagareddy; Alexander G Obukhov; Maria B Grant
Journal:  Circ Res       Date:  2019-10-15       Impact factor: 17.367

Review 4.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 5.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

6.  Adherent-Invasive E. coli enhances colonic hypersensitivity and P2X receptors expression during post-infectious period.

Authors:  Amandine Lashermes; Ludivine Boudieu; Julie Barbier; Benoit Sion; Agathe Gelot; Nicolas Barnich; Denis Ardid; Frédéric Antonio Carvalho
Journal:  Gut Microbes       Date:  2017-10-04

Review 7.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

8.  Eugenol attenuates inflammatory response and enhances barrier function during lipopolysaccharide-induced inflammation in the porcine intestinal epithelial cells.

Authors:  Qianru Hui; Emily Ammeter; Shangxi Liu; Runqiang Yang; Peng Lu; Ludovic Lahaye; Chengbo Yang
Journal:  J Anim Sci       Date:  2020-08-01       Impact factor: 3.159

Review 9.  Abnormal gut motility in inflammatory bowel disease: an update.

Authors:  G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi
Journal:  Tech Coloproctol       Date:  2020-02-15       Impact factor: 3.781

10.  Histone H3K9 methylation regulates chronic stress and IL-6-induced colon epithelial permeability and visceral pain.

Authors:  John W Wiley; Ye Zong; Gen Zheng; Shengtao Zhu; Shuangsong Hong
Journal:  Neurogastroenterol Motil       Date:  2020-08-02       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.